Wednesday, May 9, 2018

Escient Pharmaceuticals Finds $40M

San Diego-based Escient Pharmaceuticals announced Wednesday morning that it has raised $40M in a Series A funding, to develop drugs to treat neuro-immuno-inflammatory and autoreactive diseases. The funding came from The Column Group and 5AM Ventures, along with Osage University Partners. The company said the funding will go to build out its team, advance its pipeline, and progress its initial preclinical programs to clinical study. Escient pharmaceuticals said it is developing drugs based on G Protein-Coupled Receptors (GPCRs). More information »

---